Drugs / AER-01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05862623 | May 2023 → Aug 2024 | chronic obstructive pulmonary disease | Aer Therapeutics | Unknown | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-04-13 | Aer Therapeutics | Aer Therapeutics Closes $36 Million Series A to Advance Development of AER-01, an Innovative Mucolytic for the Treatment of Lung Diseases aertherapeutics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AER-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05862623 ↗ |
| Route | Inhaled | “AER-01 solution for inhalation delivered via nebulizer” NCT05862623 ↗ |